• Теги
    • избранные теги
    • Компании143
      • Показать ещё
      Страны / Регионы22
      • Показать ещё
      Формат3
      Международные организации4
      Разное27
      • Показать ещё
      Издания3
      Люди4
      Показатели1
      Сферы1
Smith & Nephew
Выбор редакции
Выбор редакции
10 августа, 10:43

Prudential helps FTSE close higher for fifth day in a row

London's leading share index closed higher, nearly reaching a 14 month high and marking its fifth straight day of gains.

Выбор редакции
14 июля, 16:30

Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical

Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical

Выбор редакции
19 мая, 18:18

Medtronic приобретет одно из подразделений Smith & Nephew

Американский производитель медицинского оборудования Medtronic договорился о приобретении подразделения Smith & Nephew, специализирующегося на производстве гинекологического оборудования. Сообщается, что сумма сделки составила примерно $350 млн.

Выбор редакции
19 мая, 12:46

Medtronic приобретет одно из подразделений Smith & Nephew

Американский производитель медицинского оборудования Medtronic договорился о приобретении подразделения Smith & Nephew, специализирующегося на производстве гинекологического оборудования. Сообщается, что сумма сделки составила примерно $350 млн.

Выбор редакции
18 мая, 15:07

Smith & Nephew to buy back up to $300 mln of its shares

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Выбор редакции
18 мая, 15:07

Smith & Nephew sells gynecology business to Medtronic for $350 mln

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Выбор редакции
13 мая, 09:15

Business takes heed as heat rises on pay

Protest votes spark long summer of talks for likes of BP, Anglo, Shire and Smith & Nephew

Выбор редакции
05 мая, 21:00

Квартальная выручка Smith & Nephew выросла на 3%

Британский производитель медицинского оборудования Smith & Nephew зафиксировал 3%-ный рост квартальной выручки. Так, выручка в первом квартале увеличилась с $1,10 млрд годом ранее до $1,14 млрд. Аналитики, в свою очередь, в среднем прогнозировали данный показатель на уровне $1,16 млрд.

Выбор редакции
05 мая, 10:13

Квартальная выручка Smith & Nephew выросла на 3%

Британский производитель медицинского оборудования Smith & Nephew зафиксировал 3%-ный рост квартальной выручки. Так, выручка в первом квартале увеличилась с $1,10 млрд годом ранее до $1,14 млрд. Аналитики, в свою очередь, в среднем прогнозировали данный показатель на уровне $1,16 млрд.

05 мая, 00:02

3 Medical Devices Stocks Set to Beat this Earnings Season

The stupendous first-quarter performance by the Medical sector is something investors definitely need to muse on.

30 апреля, 18:00

Shareholder Spring II: bosses prepare for AGM pay revolts

With the annual meeting season in full swing, companies are wondering whether investor anger will turn into a tide of protestA £23m pay deal for the chief executive of Reckitt Benckiser will come into focus this week when the Dettol-to-Durex maker puts its remuneration plans to the vote at its annual general meeting. Rakesh Kapoor’s package – twice what he received the year before – has been described by one shareholder as a misjudgment of the mood of investors, who have marked 2016 as the year they are prepared to say no to exorbitant pay deals.Boardroom bosses will be trying to gauge whether the revolts, which got this year’s season off to a blistering start, can be maintained. With BP and Smith & Nephew still reeling from No votes at the start of April, Shire Pharmaceuticals and fellow FTSE 100 member CRH were last week rebuked by investors, while in the FTSE 250, engineering firm Weir had to abandon plans to issue shares to its directors after a resounding protest. Continue reading...

25 апреля, 15:46

The Michael Pearson Era Is Officially Over: Valeant Appoints Joseph Papa As Chairman And CEO

The Michael Pearson era at Valeant is officially over. Following a week of leaks that the troubled Canadian ex-rollup will hire Perrigo's CEO, Joseph C. Papa, moments ago the company confirmed this when the VRX board said that it has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer (incidentally this comes on the day in which Periggo stock tumbled after the company slashed its 2016 EPS forecast from $9.50-$9.80 to $8.20-$8.50). The full presss release: Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Brings More Than Three Decades of Leadership and Operations Experience in Healthcare Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer.  Mr. Papa is expected to join Valeant by early May.  Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer.  Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Mr. Papa arrives at Valeant. Mr. Papa, 60, has more than 35 years of experience in the pharmaceutical, healthcare services and specialty pharmaceutical industries, including 20 years of branded prescription drug experience.  Mr. Papa has been CEO of Perrigo since 2006 and was appointed as Chairman of the Board of Directors of Perrigo in 2007. During his tenure, he led dramatic and consistent growth across the company, building it into a global leader with net sales of more than $5 billion.  Prior to Perrigo, Mr. Papa served from December 2004 to October 2006 as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc.  From 2001 to 2004, he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. While at Novartis and Pharmacia /Searle, he was responsible for overseeing  the successful launches of Diovan, Celebrex and Lotrel. Robert Ingram, Chairman of the Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time.  He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms.  In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant." "I am excited to take on the challenge of leading Valeant and helping the company chart a new course," said Mr. Papa.  "Valeant has world-class franchises, important treatments for patients across numerous therapeutic areas and a very talented and dynamic workforce, and I am confident that the company has a bright future ahead.  We have an opportunity to move forward with a renewed focus on operating with integrity across all areas of the business and providing customers with safe and affordable products that improve their lives." Mr. Papa has held management positions at DuPont Pharmaceuticals, Pharmacia Corporation, G.D. Searle & Company and Novartis AG. Mr. Papa serves as a director of Smith & Nephew, a developer of advanced medical devices. He is a graduate of the University of Connecticut with a bachelor's degree in pharmacy and he earned his MBA from Northwestern University's Kellogg Graduate School of Management.

21 апреля, 17:41

Schumpeter: Pay dirt

UK Only Article:  standard article Issue:  Can she fix it? Fly Title:  Schumpeter Main image:  20160423_WBD000_0.jpg Rubric:  Shareholders are partly responsible for the latest executive-pay brouhaha FAT cats and big bonuses routinely stoke public anger. Now shareholders are pig-wrestling mad. On April 14th investors in BP rejected a pay rise for Bob Dudley, the oil firm’s boss, furious that he had got a 20% bump in his compensation last year (pension included) for overseeing the company’s biggest-ever operating loss. “Let me be clear,” soothed Carl-Henric Svanberg, BP’s chairman. “We hear you.” BP’s shareholders are not the only ones being bolshie. On the same day, investors also slapped down Smith & Nephew, a FTSE 100 maker of medical devices, for waving through bonus payments even though targets set under its own pay policy had not been met. Fresh boardroom embarrassments loom. Shareholder-advisory firms have issued many more recommendations to vote against FTSE firms’ pay policies this year ...

21 апреля, 17:41

Pay dirt

FAT cats and big bonuses routinely stoke public anger. Now shareholders are pig-wrestling mad. On April 14th investors in BP rejected a pay rise for Bob Dudley, the oil firm’s boss, furious that he had got a 20% bump in his compensation last year (pension included) for overseeing the company’s biggest-ever operating loss. “Let me be clear,” soothed Carl-Henric Svanberg, BP’s chairman. “We hear you.” BP’s shareholders are not the only ones being bolshie. On the same day, investors also slapped down Smith & Nephew, a FTSE 100 maker of medical devices, for waving through bonus payments even though targets set under its own pay policy had not been met. Fresh boardroom embarrassments loom. Shareholder-advisory firms have issued many more recommendations to vote against FTSE firms’ pay policies this year than last. Their targets this week included Anglo American, a mining firm, whose boss presided over a loss of £3.7 billion ($5.6 billion) in 2015 but took home a bonus of almost £1m. VW’s board is trying to head off trouble at the pass: it has said it will cut bonuses significantly, given the carmaker’s emissions scandal. Citigroup is lobbying its...

Выбор редакции
18 апреля, 02:01

Sir Martin Sorrell defends £63m pay package ahead of AGM

Founder of advertising giant says his pay reflects success of WPP as shareholders gather to vote at series of high-profile annual meetingsSir Martin Sorrell, the chief executive and founder of advertising giant WPP, has launched a passionate defence of his controversial £63m bonus deal in the wake of last week’s explosive start to the annual general meeting season.Speaking after shareholders voted against pay deals at BP and Smith & Nephew on Thursday – and as boardrooms are on high alert for a potential revival of the 2012 “shareholder spring” when scores of investors rebelled over executive pay – Sorrell told the Press Association: “Most of my wealth, if not all of it, is and has been for the last 31 years tied up in the success of WPP. So if WPP does well, I do well, and others in the company do well. If we do badly, we suffer.” Continue reading...

Выбор редакции
15 апреля, 10:59

FTSE 100 bosses face fresh revolt over pay

BP and Smith & Nephew protest votes could be first of many

22 марта, 16:30

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew